Summary: ECRI and ISMP submitted comments to the USTR, emphasizing the need to prioritize patient safety and the uninterrupted supply of medical products in discussions about proposed tariffs on Chinese goods.
Key Takeaways:
- ECRI and ISMP urged the USTR to consider the adverse impacts of trade policy on patient safety and the supply of medical products.
- The organizations stressed the importance of balancing trade policies with maintaining a stable supply of essential health products to protect public health.
ECRI submitted comments in response to the US Trade Representative (USTR)’s solicitation for input on proposed tariffs affecting $18 billion worth of goods manufactured in China, including medical products.
Emphasis on Patient Safety
ECRI and the Institute for Safe Medication Practices (ISMP) urged the USTR to carefully consider potential adverse impacts of trade policy on patient safety as it relates to pharmaceuticals, medical devices, and healthcare supplies. The feedback emphasized that patient safety and the uninterrupted supply of health-related products must be prioritized in any policy discussions about trade restrictions and tariffs.
Availability of Medical Products
ECRI and ISMP’s stance highlights the critical need to ensure the availability of medical products, such as syringes and their accessories, personal protective equipment, and other essential medical supplies.
Balancing Trade Policies
ECRI and ISMP’s position underscores the importance of balancing trade policies with the need to maintain a stable supply of critical health products to safeguard public health and ensure that patient care is not compromised.
